Aspirin contributes to improved CVD outcomes for people with type 2 diabetes

Dp3

Aspirin as part of a cardiovascular (CVD) prevention strategy has contributed towards a reduction in the risk of having a myocardial infarction (MI) in people with type 2 diabetes over the last 15 years. This Danish study, presented as a late breaker at the European Society of Cardiologists (ESC), is the first to examine the […]

Dr Andrew Chan receives prestigious National Cancer Institute Outstanding Investigator Award

Chan

The National Cancer Institute (NCI) has named International Aspirin Foundation’s Scientific Advisory Board member Andrew Chan MD MPH one of the 2020 recipients of its prestigious Outstanding Investigator Award (OIA). The NCI OIA is one of the most highly regarded research awards available to cancer investigators in the USA. The highly competitive award supports accomplished […]

Evidence that less is more – aspirin alone as an antiplatelet strategy to prevent clotting after a heart valve intervention

Dp2

Results from the POPular TAVI trial, presented as a Hot Line session at this year’s European Society of Cardiologists (ESC) Congress, have shown aspirin monotherapy to be superior to dual therapy with clopidogrel as an anti-platelet strategy, in people not on oral anticoagulants, following transcatheter aortic valve implantation (TAVI) for aortic stenosis. In this study, […]

NICE provide a patient decision aid for aspirin and Lynch syndrome

Dp5

In order to support the implementation of their colorectal cancer (CRC) guidelines, the National Institute for Health and Care Excellence (NICE), have published a patient decision aid to help clinicians enable people with Lynch syndrome to make fully informed choices about whether to take regular aspirin in order reduce their chance of getting bowel cancer. […]

Long-term daily aspirin helps prevent hereditary colorectal cancer

Dp5

Long-term follow-up of the CAPP2 study demonstrates the benefits of daily aspirin for preventing hereditary colorectal cancer (Lynch syndrome)  CAPP2 is an international, double-blind, randomised, placebo-controlled registry-based study of cancer prevention in people with Lynch syndrome. Lynch syndrome is a hereditary genetic condition which increases the person’s risk of developing certain cancers. The 10 year […]

Meta-analysis concludes that monotherapy with low-dose aspirin is comparable with P2Y12 inhibitor monotherapy for the secondary prevention of cardiovascular disease -confirming aspirin’s place as a cost effective drug of choice.

Dp2

Chiarito and colleagues conducted a systematic review and meta-analysis of all randomised trials that compare P2Y12 inhibitors with low-dose aspirin monotherapy for the prevention of secondary cardiovascular (CV) events in patients with established cerebrovascular, coronary or peripheral artery disease with the aim of finding the optimal regimen. The researchers found nine trials with a total […]

Pioneering low-dose aspirin research group to receive Senior Science Award 2020

Awards

The scientists responsible for first trials of low-dose daily aspirin to prevent coronary and cerebrovascular events have been recognised with the International Aspirin Foundation’s Senior Science Award 2020. Professors Lars Wallentin, Jan van Gijn, Bo Norrving and Tom Meade led four pivotal trials across Sweden, the Netherlands and the UK in the 1980s. Together, these […]